FRIDAY, Jan. 6, 2023 (HealthDay News) — The U.S. Food and Drug Administration on Friday approved a second Alzheimer’s drug, lecanemab, despite reports of rare brain bleeds linked to use of the drug in some patients. However, the FDA pointed to the drug’s benefits, as well. “Alzheimer’s disease immeasurably incapacitatesContinue Reading

FRIDAY, Jan. 6, 2023 (HealthDay News) — An antidote to teenage depression might be found in school gymnasiums and on sports fields, a major new review argues. Supervised exercise programs are associated with significant reductions in symptoms of depression among children and teenagers, according to the analysis of data fromContinue Reading

THURSDAY, Jan. 5, 2023 (HealthDay News) — A short but intensive approach to “talk therapy” can help many combat veterans overcome post-traumatic stress disorder (PTSD), a new clinical trial has found. The study tested “compressed” formats of a standard PTSD treatment called prolonged exposure therapy, in which patients learn toContinue Reading

THURSDAY, Jan. 5, 2023 (HealthDay News) — Lecanemab: It’s an experimental medication that’s been shown in trials to slow cognitive decline in people with Alzheimer’s disease. It’s also up for accelerated approval by the U.S. Food and Drug Administration, with a decision expected by Jan. 6. However, the drug hasContinue Reading

WEDNESDAY, Jan. 4, 2023 (HealthDay News) — Sometimes it really does “take a village” to help you meet life’s challenges, and quitting smoking can be one of the toughest challenges out there. That’s why specially designed smoking-cessation programs can make all the difference, experts say. Many programs employ a combinationContinue Reading